|

BLU-924 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: SAR449336

Pipeline

Phase 1/2: 1

Top Sponsors

  • Blueprint Medicines Corporation1

Indications

  • Pancreatic Ductal Adenocarcinoma1
  • Colorectal Neoplasms1
  • Advanced Solid Tumor1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1

Fairfax, Virginia1 trial

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Next Oncology Virginia Cancer Specialist

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.